(Q35841043)

English

EGFR-mediated re-activation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition with vemurafenib

scientific article published on 16 January 2012

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

10 August 2017

EGFR-mediated re-activation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition with vemurafenib (English)

1 reference

Europe PubMed Central

PMC publication ID

10 August 2017

Mari Mino-Kenudson

15

object named as

Mari Mino-Kenudson

0 references

11

object named as

Keith T Flaherty

1 reference

Europe PubMed Central

PMC publication ID

10 August 2017

Dora Dias-Santagata

9

object named as

Dora Dias-Santagata

1 reference

Europe PubMed Central

PMC publication ID

10 August 2017

Jeffrey A Engelman

16

object named as

Jeffrey A Engelman

1 reference

Europe PubMed Central

PMC publication ID

10 August 2017

Ryan B Corcoran

1

object named as

Ryan B Corcoran

1 reference

Europe PubMed Central

PMC publication ID

10 August 2017

Jeffrey Settleman

14

object named as

Jeffrey Settleman

1 reference

Europe PubMed Central

PMC publication ID

10 August 2017

13

object named as

Jennifer A Wargo

1 reference

Europe PubMed Central

PMC publication ID

10 August 2017

12

object named as

Adriano Piris

1 reference

Europe PubMed Central

10 August 2017

PMC publication ID

author name string

Hiromichi Ebi

2

1 reference

Europe PubMed Central

PMC publication ID

10 August 2017

Alexa B Turke

3

1 reference

Europe PubMed Central

PMC publication ID

10 August 2017

Erin M Coffee

4

1 reference

Europe PubMed Central

PMC publication ID

10 August 2017

Michiya Nishino

5

1 reference

Europe PubMed Central

PMC publication ID

10 August 2017

Alexandria P Cogdill

6

1 reference

Europe PubMed Central

PMC publication ID

10 August 2017

Ronald D Brown

7

1 reference

Europe PubMed Central

PMC publication ID

10 August 2017

Patricia Della Pelle

8

1 reference

Europe PubMed Central

PMC publication ID

10 August 2017

Kenneth E Hung

10

1 reference

Europe PubMed Central

PMC publication ID

10 August 2017

publication date

16 January 2012

1 reference

Europe PubMed Central

PMC publication ID

10 August 2017

Cancer Discovery

1 reference

Europe PubMed Central

PMC publication ID

10 August 2017

2

1 reference

Europe PubMed Central

PMC publication ID

10 August 2017

3

1 reference

Europe PubMed Central

PMC publication ID

10 August 2017

227-235

1 reference

Europe PubMed Central

PMC publication ID

10 August 2017

Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3308191

27 July 2018

Basal and treatment-induced activation of AKT mediates resistance to cell death by AZD6244 (ARRY-142886) in Braf-mutant human cutaneous melanoma cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3308191

27 July 2018

Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3308191

27 July 2018

Inhibition of Mutated, Activated BRAF in Metastatic Melanoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3308191

27 July 2018

RG7204 (PLX4032), a selective BRAFV600E inhibitor, displays potent antitumor activity in preclinical melanoma models

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3308191

27 July 2018

Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3308191

27 July 2018

RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3308191

27 July 2018

Intermolecular interactions of Sprouty proteins and their implications in development and disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3308191

27 July 2018

Targeting the RAF-MEK-ERK pathway in cancer therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3308191

27 July 2018

Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3308191

27 July 2018

Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3308191

27 July 2018

The extracellular signal-regulated kinase: multiple substrates regulate diverse cellular functions

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3308191

27 July 2018

In vivo antitumor activity of NVP-AEW541-A novel, potent, and selective inhibitor of the IGF-IR kinase

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3308191

27 July 2018

Mutations of the BRAF gene in human cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3308191

27 July 2018

Receptor tyrosine kinases exert dominant control over PI3K signaling in human KRAS mutant colorectal cancers

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3308191

24 September 2018

Value of mismatch repair, KRAS, and BRAF mutations in predicting recurrence and benefits from chemotherapy in colorectal cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3308191

24 September 2018

BRAF gene amplification can promote acquired resistance to MEK inhibitors in cancer cells harboring the BRAF V600E mutation

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3308191

24 September 2018

RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3308191

24 September 2018

Identifiers

10.1158/2159-8290.CD-11-0341

1 reference

Europe PubMed Central

PMC publication ID

10 August 2017

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

10 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

10 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q35841043&oldid=2119045618"